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Abstract
Background: Infectious diseases continue to impact human health and life expectancy. Currently, there are
numerous methicillin-resistant Staphylococcus aureus (MRSA) strains with multiple antibiotic resistance
which presents a major concern to human health. Thus, treatment is becoming increasingly difficult as so
many bacterial organisms present resistance to current antibiotics. Combination therapy has been used to
limit the emergence of antibiotic resistant strains. Manuka honey is a unique honey produced in New
Zealand. It has demonstrated inhibition of growth in vitro including S. aureus and Pseudomonas aeruginosa, two
bacteria common in skin wound infections. The combined use of manuka honey and antibiotics ought to limit
further emergence of antibiotic resistance. What is the efficacy of the combination of manuka honey and
antibiotic therapy in treatment of MRSA skin infections?
Methods: A comprehensive search of available medical literature was conducted using Medline-OVID,
PubMed, and Web of Science using the keywords: manuka honey and MRSA. The search was then narrowed
to include only English language articles. The bibliographies of the articles were further searched for relevant
sources. Articles with primary data evaluating the efficacy of manuka honey’s impact in topical treatment of
MRSA skin infections along with combination antibiotic therapy were included.
Results: The initial result of the search yielded 29 articles for review. After screening articles for relevance, a
total of three articles met inclusion criteria. These articles include three in vitro studies analyzing the synergy
of manuka honey and specific antibiotics in treatment of bacterial skin infections. All studies demonstrated a
synergistic effect between manuka honey and various antibiotics against MRSA skin infections.
Conclusion: The use of antibiotics and manuka honey has demonstrated in vitro to eradicate varieties of
MRSA strains. Combination therapy has been proven to limit the emergence of antibiotic resistance during
therapy, increase synergism and efficacy of treatment, and reduce the amount of each antibiotic used. Manuka
honey is a viable adjunct to modern medicinal treatment of wound pathogens which will reduce treatment
costs and limit side effects. Controlled clinical studies are needed to investigate the synergism between
manuka honey and antibiotics in vivo before potential introduction as a standard of care.
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Abstract   
 
Background: Infectious diseases continue to impact human health and life expectancy. 
Currently, there are numerous methicillin-resistant Staphylococcus aureus (MRSA) 
strains with multiple antibiotic resistance which presents a major concern to human 
health. Thus, treatment is becoming increasingly difficult as so many bacterial organisms 
present resistance to current antibiotics.  Combination therapy has been used to limit the 
emergence of antibiotic resistant strains. Manuka honey is a unique honey produced in 
New Zealand. It has demonstrated inhibition of growth in vitro including S. aureus and 
Pseudomonas aeruginosa, two bacteria common in skin wound infections. The combined 
use of manuka honey and antibiotics ought to limit further emergence of antibiotic 
resistance. What is the efficacy of the combination of manuka honey and antibiotic 
therapy in treatment of MRSA skin infections? 
 
 
Methods:  A comprehensive search of available medical literature was conducted using 
Medline-OVID, PubMed, and Web of Science using the keywords: manuka honey and 
MRSA. The search was then narrowed to include only English language articles.  The 
bibliographies of the articles were further searched for relevant sources. Articles with 
primary data evaluating the efficacy of manuka honey’s impact in topical treatment of 
MRSA skin infections along with combination antibiotic therapy were included. 
 
Results:  The initial result of the search yielded 29 articles for review. After screening 
articles for relevance, a total of three articles met inclusion criteria. These articles include 
three in vitro studies analyzing the synergy of manuka honey and specific antibiotics in 
treatment of bacterial skin infections. All studies demonstrated a synergistic effect 
between manuka honey and various antibiotics against MRSA skin infections. 
 
Conclusion:  The use of antibiotics and manuka honey has demonstrated in vitro to 
eradicate varieties of MRSA strains.  Combination therapy has been proven to limit the 
emergence of antibiotic resistance during therapy, increase synergism and efficacy of 
treatment, and reduce the amount of each antibiotic used.  Manuka honey is a viable 
adjunct to modern medicinal treatment of wound pathogens which will reduce treatment 
costs and limit side effects. Controlled clinical studies are needed to investigate the 
synergism between manuka honey and antibiotics in vivo before potential introduction as 
a standard of care.  
 
 
Keywords: Manuka honey, MRSA  
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The Efficacy of Topical Manuka Honey and Combination 
Antibiotic Therapy in Treatment of MRSA Skin Infections  
 
BACKGROUND 
 
 Infectious diseases continue to impact human health and life expectancy.  In 1961, 
methicillin resistance was discovered in Staphylococcus aureus. Currently, there are 
numerous Methicillin-resistant Staphylococcus aureus (MRSA) strains with multiple 
antibiotic resistance which presents a major concern to human health.1 Thus, treatment is 
becoming increasingly difficult as so many bacterial organisms present resistance to 
current antibiotics.1 S. aureus is one of the main causative agents of critical acute and 
chronic skin infections.2 In the United States alone, chronic wound infections affect 6.5 
million patients and cost the United States $25 billion annually with an increase in 
estimated future costs.3 
 Combination therapy has been used to limit the emergence of antibiotic resistant 
strains as the use of at least two antibiotics with differing methods of action promotes an 
increase of bacterial death secondary to each organism possessing fewer traits necessary 
to survive. This reduces the risk of achieving antibiotic resistance during therapy as each 
mode of action affects the bacteria differently.4 Combination therapy can promote 
increased synergism and thus improve the efficacy of treatment as well as reduce the 
amount of each antibiotic used. This will reduce treatment costs and limit side effects 
associated with antibiotic use.5 These improvements are exceptionally important for 
chronic wounds as they require long-term antibiotic therapy.  
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 Honey is a possible treatment option for synergistic activity with antibiotics.6 It is 
a broad-spectrum antibacterial agent used among multiple wound pathogens.4  Medical-
grade honey has been first licensed for wound care treatment in Australia in 1999 and has 
extended to Canada, Hong Kong, Europe, New Zealand and the United States.7  
Currently, honey is available as a licensed medical device and is used in conjunction with 
sterile dressings or sterilized in tubes.5   
Manuka honey is a unique honey produced in New Zealand which is derived from 
the nectar collected by honey bees rummaging in the manuka shrub native to New 
Zealand.1,2 It has demonstrated inhibition of growth in vitro including S. aureus and 
Pseudomonas aeruginosa, two bacteria common in skin wound infections.4 Two 
components, methylglyoxal and leptosin, have been recently identified to contribute to 
manuka honey’s antibacterial properties, yet further bioactive factors have not yet been 
discovered.1  Manuka honey has already demonstrated lack of resistance to honey-
resistant strains. The combined use of manuka honey and antibiotics should limit further 
emergence of antibiotic resistance.7 What is the efficacy of the combination of manuka 
honey and antibiotic therapy in treatment of MRSA skin infections? 
METHODS 
A comprehensive search of available medical literature was conducted using 
Medline-OVID, PubMed, and Web of Science using the keywords: manuka honey and 
MRSA. The search was then narrowed to include only English language articles.  The 
bibliographies of the articles were further searched for relevant sources. Articles with 
primary data evaluating the efficacy of manuka honey’s impact in topical treatment of 
MRSA skin infections along with combination antibiotic therapy were included.  
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Studies included the general population infected with MRSA or in vitro MRSA 
bacterial strands treated with manuka honey, use of antibiotics in combination with 
manuka honey, and resolution of infection. Excluded were studies that were in a non-
English language, systemic MRSA infections, and use of strictly oral antibiotics.  
RESULTS 
 The initial result of the search yielded 29 articles for review. After screening 
articles for relevance, a total of three articles met inclusion criteria. These articles include 
three in vitro studies5,8,9 analyzing the synergy of manuka honey and specific antibiotics 
in treatment of bacterial skin infections.  
Synergy Between Oxacillin and Manuka Honey Sensitizes MRSA to Oxacillin 
  This in vitro study8 investigated an array of different laboratory techniques to 
assess the inhibitory effects of both manuka honey and oxacillin on bacterial MRSA 
strands when used in combination or separately.  EMRSA-15 strands were tested against 
manuka honey, oxacillin, and a combination of both manuka honey and oxacillin.  Etest 
strips, disk diffusion, chequerboards, growth curves, and serial broth dilutions were used 
to assess the inhibition of MRSA. This study intended to explore the possibility of a 
synergistic effect of oxacillin and manuka honey on MRSA growth.8  
 Sub-inhibitory concentrations of sterile, antibiotic-free manuka honey (2.5% and 
5%) were determined by serial doubling dilutions; whereas the minimum-inhibitory 
concentrations (MIC) of oxacillin was determined by serial doubling dilutions and with 
oxacillin Etest strips. Chequerboards were used to assess synergism of MRSA inhibition 
between manuka honey and oxacillin. A fractional inhibition concentration index (FIC) 
was used to determine which interactions had a synergistic interaction. A FIC ≤ 0.5 
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indicates synergy; >0.5 to ≤4, additivity; and >4, antagonism. Time-kill curves were 
performed using varied concentrations of manuka honey and oxacillin.8 
 The MIC of manuka honey was 6% determined by broth dilution. AST, Etest 
strips, and broth dilution resulted in resistance of MRSA to oxacillin; however, there was 
a reversal of oxacillin susceptibility in MRSA with the addition of manuka honey. The 
best combination of MIC of manuka honey (5% weight/volume (w/v)) and oxacillin 
(0.25mg/L) prevented growth of MRSA. These FIC values were ≤ 0.5 which indicated a 
synergistic effect between manuka honey and oxacillin to inhibit MRSA growth.8  
Synergism Between Medihoney and Rifampicin Against MRSA  
This in vitro study9 investigated the effects of a combination treatment of 
rifampicin, honey (sugar solution), and manuka honey when used to inhibit MRSA 
strains. An MIC for each of agent used was defined as the least amount of agent to inhibit 
MRSA. Checkerboard microdilution assays, agar diffusion tests, and time-kill curves 
were used to determine each MIC and thus the antibacterial effects of each agent on 
MRSA.9   
Checkerboard microdilution assays performed indicated a decrease in resistance 
against rifampicin when used in combination with manuka honey against MRSA.9 The 
corresponding FIC was ≤ 0.5 demonstrating synergism. The MIC for manuka honey was 
determined to be 8% (w/v). When rifampicin was used in combination with a sugar 
solution replicating honey, the data indicated no synergistic effect. Further analysis with 
time-curve assays confirmed a synergistic effect between rifampicin and manuka honey 
with a decreased MIC of 7% (w/v). Agar diffusion tests, which measured a mean 
diameter of inhibitory zone of each agent, confirmed the above results of synergism 
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between rifampicin and manuka honey; however, it also indicated that manuka honey, 
when used alone, had no significant effect on the growth of MRSA on the agar plates.9  
A checkerboard microdilution assay was performed to determine if methylglyoxal 
(MGO) is the sole antimicrobial component of manuka honey. The results indicated that 
an amount of 150-160 µg/mL of MGO, comparable to the amount of 16-17% (w/v) of 
MGO in manuka honey, displayed an inhibitory component against MRSA strains; 
however, the combination of rifampicin and MGO did not demonstrate a synergistic 
effect against MRSA strains.  Rifampicin and MGO used in the presence of sugar, a main 
component of manuka honey, demonstrated a decreased FIC >1, thus indicating weaker 
synergism when in presence of sugar.9  
An agar disk diffusion assay was performed to investigate if manuka honey was 
able to restore resistance to rifampicin, as it had been proven with oxacillin.8 No 
inhibition zones could be demonstrated around rifampicin disk in contrast to the 25mm 
diameter zones that appeared around oxacillin disks.9  
Time-kill experiments demonstrated antimicrobial activity of rifampicin against 
MRSA; however, at 24 hours the bacterial level of MRSA strains displayed growth to a 
level consistent with normal growth of MRSA. When used in combination with manuka 
honey, the MRSA bacteria resulted in a complete inhibition of growth.9  
Improving Antibiotic Activity Against Wound Pathogens With Manuka Honey in 
Vitro 
 This in vitro study5 investigated the potential synergistic interaction of 15 
different antibiotics when used in combination with manuka honey against both MRSA 
and Pseudomonas aeruginosa. See Figure I. This interaction was tested using disc 
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diffusion, broth dilution, Etest strips, chequerboard titration, and growth curves. A MIC 
was discovered to be 6% (w/v) for manuka honey against MRSA and 1% below the MIC 
were used for testing in combination with antibiotics.5  
 Disc diffusion was used to assess antibiotic susceptibility when used in 
combination with manuka honey. The greatest zones of inhibition present against MRSA 
were rifampicin, piperacillin/tazobactam, imipenem, mupirocin, and tetracycline. 
However, this study did not pursue further testing with rifampicin and 
piperacillin/tazobactam as broth dilution demonstrated an additive yet not synergistic 
effect. This study preferred to focus on single antibiotics in combination with manuka 
honey. Therefore, the evidence suggests that manuka honey used in combination with 
tetracycline, imipenem, and mupirocin demonstrate the greatest synergistic effects.5  
 Imipenem and manuka honey displayed a synergistic effect against MRSA but 
had no effect against P. aeruginosa. Tetracycline and manuka honey demonstrated the 
greatest synergistic effects towards both bacteria.5  
DISCUSSION 
 
The potential use of manuka honey in combination with antibiotics creates a 
promising avenue of treatment against MRSA infections. Although the literature in this 
systematic review included only in vitro studies, the overall results demonstrate 
overwhelming evidence of eradication of MRSA bacteria. In just the small amount of 
time between publications assessed in this review, a mere 23 months, the evolving impact 
of manuka honey has greatly expanded.  
In the study discussing the synergism between oxacillin and manuka honey,8 it 
was shown that MRSA displays resistance against oxacillin; furthermore, when used in 
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combination with manuka honey, it enhances the susceptibility of MRSA to oxacillin. In 
the laboratory experiments, a MIC of 6% (w/v) was discovered as a sub-lethal 
concentration of manuka honey. Since honey can be used undiluted in dressings to wrap 
chronic venous ulcerations or MRSA skin infections, 6% concentration of manuka honey 
is easily attainable. In addition to the synergism displayed by both agents against MRSA, 
manuka honey has been shown to restore susceptibility of MRSA to oxacillin. Laboratory 
results have shown that honey down-regulates the mecR1 gene, a gene known to promote 
methicillin resistance in MRSA. This study hypothesizes that the down-regulation of this 
gene directly decreases the resistance of MRSA to oxacillin.8 
 In the study discussing synergism between manuka honey and rifampicin,9 it 
demonstrated a combined effect of complete inhibition of MRSA growth. The MIC for 
manuka honey was 8% (w/v) indicating that an undiluted topical application of the honey 
would be feasible. While MGO may present as a powerful ingredient in manuka honey, 
this study demonstrates that it is not the sole component of its broad-spectrum 
antibacterial effects. Since MGO and rifampicin had an additive, yet not synergistic effect 
against MRSA and an even weaker effect in presence of sugar, it has been surmised that 
manuka honey contains other ingredients that give its antimicrobial activity. The 
chemical breakdown of manuka honey most likely has components that act together 
synergistically; however, when isolated, each component may behave differently when 
affecting bacterial growth.9 It has been postulated that hydrogen peroxide and other 
active substances that have yet to be defined contribute to its broad-spectrum activity.6  
 MRSA can develop resistance to rifampicin just after one dosage. This study9 
provides evidence that when rifampicin is used in the presence of manuka honey, MRSA 
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strains do not develop resistance to rifampicin. Unlike manuka honey’s unique resistance 
restoration properties evident when used in combination with oxacillin, it is not able to 
improve susceptibility to rifampicin.8,9 However, if used with the initial dose of 
rifampicin and subsequent dosing, MRSA will not develop rifampicin resistance. In long 
term therapy, this combination may reduce the incidence of rifampicin resistance in clinic 
and the environment.9 
 The final study5 assessed antibiotic activity against both MRSA and P. aerginosa 
with manuka honey. Fifteen antibiotics were used in combination with manuka honey 
against both wound pathogens. Results initially demonstrated synergistic effects against 
MRSA with use the combined use of tetracycline, mupirocin, and imipenem, rifampicin, 
and piperacillin/tazobactam. Rifampicin showed an additive, but not synergistic effect, 
and initial results showed piperacillin/tazobactam to be synergistic as well.5 These 
findings of rifampicin’s activity contradict results found in a later study conducted by 
Muller et al.9 However, more comprehensive laboratory studies were conducted in the 
latter publication which proved rifampicin to be synergistic with manuka honey.9 This 
study chose to focus on single antibiotics and thus, did not conduct further testing with 
piperacillin/tazobactam.5 
 Imipenem and manuka honey had the greatest synergistic activity against MRSA. 
However, it did not affect P. aerginosa. Tetracycline and manuka honey demonstrated 
the most powerful synergistic effect on both pathogens. As both bacterial organisms are 
nosocomial infections prevalent in the hospital setting, it may be difficult to isolate one 
organism when treating a skin bacterial infection until after culture results are known. 
Since wounds, such as chronic venous ulcerations, tend to maintain a variety of 
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polymicrobial communities, a broad-spectrum antibiotic like tetracycline may be the best 
choice of antibiotic to investigate in the future as it affects both organisms tested.5 
 The primary weakness of the literature reviewed is its shared methodology of 
being in vitro studies. What is the clinical application of in vitro studies? Its application 
to practice is not clear. There have been concerns about the artificial non-physiologic 
conditions the cells are maintained in, potential impairment of intracellular signaling, 
compromise in homeostatic culture conditions, and too rapid of cellular growth. Since in 
vitro testing may not be the most accurate replication of human tissue, the most beneficial 
representation of testing should be studied in vitro and in vivo, respectively, to 
demonstrate a more detailed and widespread picture.10 
CONCLUSION 
 
  The use of antibiotics and manuka honey has demonstrated in vitro to eradicate 
varieties of MRSA strains and have bactericidal effects against Pseudomonas aerginosa.  
Combination therapy has been proven to limit the emergence of antibiotic resistance 
during therapy, increase synergism and efficacy of treatment, and reduce the amount of 
each antibiotic used.  Manuka honey is a viable adjunct to modern medicinal treatment of 
wound pathogens which will reduce treatment costs and limit side effects. 
 Currently, all literature has demonstrated overwhelming support for trials of 
combination therapy in vitro.  Further investigation is needed to define the underlying 
mechanism of action of manuka honey and synergistic interaction with various 
antibiotics. Controlled clinical studies are needed to investigate the synergism between 
manuka honey and antibiotics in vivo before potential introduction as a standard of care.  
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Figures 
Figure I:    Antibiotic sensitivity testing of EMRSA-15 by disc diffusion. 
 
Permission received by author, Rowena Jenkins. Contacted at 
rojenkins@cardiffmet.ac.uk 
 
 
 
 
 
 
